Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates

Summary

Healthcare reform is upon the United States (US) healthcare system. Prioritisation of preventative efforts will guide necessary transitions within the US healthcare system. While annual deep-vein thrombosis (DVT) costs have recently been defined at the US national level, annual pulmonary embolism (PE) and venous thromboembolism (VTE) costs have not yet been defined. A decision tree and cost model were developed to estimate US health care costs for total PE, total hospital-acquired PE, and total hospital-acquired “preventable” PE. The previously published DVT cost model was modified, updated and combined with the PE cost model to elucidate the same three categories of costs for VTE. Direct and indirect costs were also delineated. For VTE in the base model, annual cost ranges in 2011 US dollars for total, hospital-acquired, and hospital-acquired “preventable” costs and were $13.5-$27.2, $9.0-$18.2, and $4.5-$14.2 billion, respectively. The first sensitivity analysis, with higher incidence rates and costs, demonstrated annual US total, hospital-acquired, and hospital-acquired “preventable” VTE costs ranging from $32.1-$69.3, $23.7-$51.5, and $11.9-$39.3 billion, respectively. The second sensitivity analysis with long-term attack rates (LTAR) for recurrent events and post-thrombotic syndrome and chronic pulmonary thromboembolic hypertension demonstrated annual US total, hospital-acquired, and hospital-acquired “preventable” VTE costs ranging from $15.4-$34.4, $10.3-$25.4, and $5.1-$19.1 billion, respectively. PE costs comprised a majority of the VTE costs. Prioritisation of effective VTE preventative strategies will reduce significant costs, morbidity and mortality within the US healthcare system. The cost models may be utilised to estimate other countries’ costs or VTE-specific disease states.

Keywords

Cost model - venous thomboembolism - pulmonary embolism - deep-vein thrombosis - preventable costs - annualised - long-term attack rates - adverse event

• References

• 1 Shojania KG. et al. Making health care safer: a critical analysis of patient safety practices. Evid Rep Technol Assess 2001; 43 i-x 1-668.
• 2 Heit JA. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a populationbased study. Arch Intern Med 2002; 162: 1245-1248.
• 3 Anderson Jr FA. et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82: 777-782.
• 4 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23) (Suppl. 01) I4-8.
• 5 Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 1996; 93: 2212-2245.
• 6 Heit JA. et al. on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood (ASH Annual Meeting Abstracts). 2005 106. Abstract 910.
• 7 US Department of Health and Human Services (HHS). surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism 2008. Available at http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf Accessed February 10th, 2012.
• 8 Cohen AT. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
• 9 Spencer FA. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
• 10 Spencer FA. et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007; 167: 1471-1475.
• 11 Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93: 259-262.
• 12 Geerts WH. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (06) 381S-453S.
• 13 Collins R. et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162-1173.
• 14 Mismetti P. et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 913-930.
• 15 Arnold DM. et al. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 2001; 120: 1964-1971.
• 16 Shackford SR. et al. A 10-year analysis of venous thromboembolism on the surgical service: the effect of practice guidelines for prophylaxis. Surgery 2008; 144: 3-11.
• 17 Mahan CE. et al. Venous Thromboembolism Pharmacy Intervention Management Program With an Active, Multifaceted Approach Reduces Preventable Venous Thromboembolism and Increases Appropriate Prophylaxis. Clin Appl Thromb Hemost 2012; 18: 45-58.
• 18 Maynard GA. et al. Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model. J Hosp Med 2010; 05: 10-18.
• 19 Qaseem A. et al. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011; 155: 625-632.
• 20 Lederle FA. et al. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2011; 155: 602-615.
• 21 Falck-Ytter Y. et al. Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) e278S-325S.
• 22 Gould MK. et al. Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 141. 2 Suppl e227S-77S.
• 23 Kahn SR. et al. Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) e195S-226S.
• 24 Mahan CE. et al. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost 2011; 106: 405-415.
• 25 Grosse SD. Incidence-based cost estimates require population-based incidence data. A critique of Mahan et al. Thromb Haemost 2012; 107: 192-193.
• 26 Mahan CE. et al. Long-term attack rates, as compared with incidence rates, may provide improved cost-estimates in venous thromboembolism. A reply to S. D. Grosse. Thromb Haemost 2012; 107: 194-195.
• 27 Amin A. et al. Thromboprophylaxis rates in US medical centers: success or failure?. J Thromb Haemost 2007; 05: 1610-1616.
• 28 Yu HT. et al. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm 2007; 64: 69-76.
• 29 Amin A. et al. Appropriate thromboprophylaxis in hospitalized cancer patients. Clin Adv Hematol Oncol 2008; 06: 910-920.
• 30 Amin A. et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis 2010; 29: 326-339.
• 31 US TJC VTE Core Measures. Available at http://www.jointcommission.org/venous_thromboembolism Accessed February 10th, 2012.
• 32 Centers for Disease Control and Prevention. National Center on Birth Defects and Developmental Disabilities Strategic Plan 2011-2015. Available at http://www.cdc.gov/NCBDDD/AboutUs/documents/NCBDDD_StrategicPlan_2-10-11.pdf Accessed February 10th, 2012.
• 33 National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism: Additional Performance Measures. Available at http://www.qualityforum.org/Publications/2008/10/National_Voluntary_Consensus_Stan-dards_for_Prevention_and_Care_of_Venous_Thromboembolism__Additional_Performance_Measures.aspx Accessed February 10th, 2012.
• 34 CMS Factsheet. August 2011. „IMPROVING QUALITY OF CARE DURING INPATIENT HOSPITAL STAYS.”. Available at http://www.cms.gov/apps/media/press/factsheet.asp?Counter=4040&intNumPerPage=10&checkDate=&check-Key=&srchType=1&numDays=3500&srchOpt=0&srchData=&keyword-Type=All&chkNewsType=6&intPage=&showAll=&pYear=&year=&desc=false&cboOrder=date Accessed February 10th, 2012.
• 35 Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007; 13: 475-486.
• 36 Heit JA. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-768.
• 37 Prandoni P. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
• 38 Carrier M. et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152: 578-589.
• 39 Douketis JD. et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007; 147: 766-774.
• 40 Douketis JD. et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. J Am Med Assoc 1998; 279: 458-462.
• 41 Creekmore FM. et al. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy 2006; 26: 1438-1445.
• 42 Baroletti S. et al. Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost 2008; 100: 1130-1135.
• 43 Bullano MF. et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005; 11: 663-673.
• 44 Willey VJ. et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004; 26: 1149-1159.
• 45 Pengo V. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
• 46 Dentali F. et al. Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 2009; 124: 256-258.
• 47 Ambrisentan (Letairis) for pulmonary arterial hypertension. Med Lett Drugs Ther. 2007 49. 87-88.
• 48 Kirson NY. et al. Excess costs associated with patients with chronic thromboem-bolic pulmonary hypertension in a US privately insured population. Appl Health Econ Health Policy 2011; 09: 377-387.
• 49 McLaughlin VV. et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.
• 50 Guanella R. et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost 2011; 09: 2397-2405.
• 51 Braekkan SK. et al. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study. J Thromb Haemost 2008; 06: 1851-1857.
• 52 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 05: 692-699.
• 53 Park B. et al. Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample. Chest 2009; 136: 983-990.
• 54 Tom's Inflation Calculator. available at http://www.halfhill.com/inflation.html Accessed February 10th, 2012.
• 55 Anderson Jr FA. et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-938.
• 56 Bradley CJ. et al. Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst 2008; 100: 1763-1770.
• 57 Max W. et al. Valuing Human Life: Estimating the Present Value of Lifetime Earnings, 2000. Center for Tobacco Control Research and Education. Economic Studies and Related Methods. 2004 http://repositories.cdlib.org/ctcre/esarm/PVLE2000 Accessed February 10th, 2012.
• 58 Donze J. et al. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost 2008; 100: 943-948.
• 59 Ashrani AA, Heit JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis 2009; 28: 465-476.
• 60 Phillips T. et al. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol 1994; 31: 49-53.
• 61 Mahan CE, Fanikos J. New antithrombotics: the impact on global health care. Thromb Res 2011; 127: 518-524.
• 62 Weitz JI. et al. New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) e120S-51S.
• 63 Fondaparinux Generic in US. Available at http://www.alchemia.com.au/irm/content/products.html Accessed April 16th 2012.
• 64 National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Technology appraisal guidance 157. London: NICE. 2008 September.
• 65 National Institute for Health and Clinical Excellence. Riv- aroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. Tech- nology appraisal guidance 170. London: NICE. 2009 April.
• 66 National Institute for Health and Clinical Excellence. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. Technology appraisal guidance 245. London: NICE. 2012 January.
• 67 Scottish Medicines Consortium. Drug advice: dabigatran etexilate, 75mg and 110mg hard capsules (Pradaxa). Glasgow: SMC. 2008 May.
• 68 Scottish Medicines Consortium. Drug advice: rivaroxaban 10 mg film-coated tablets (Xarelto). Glasgow: SMC. 2008 Nov.
• 69 Diamantopoulos A. et al. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost 2010; 104: 760-770.
• 70 Duran A. et al. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. J Med Econ 2011; 14: 824-834.
• 71 Holmes M. et al. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Technol Assess 2009; 13 (Suppl. 02) 55-62.
• 72 Holmes M. et al. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal. Pharmacoeconomics 2012; 30: 137-146.
• 73 Lereun C. et al. An indirect comparison, via enoxaparin, of rivaroxaban with da-bi g atr an in t he pre vention of venous t hrom b o embolism afte r hi p or knee repl ace-ment. J Med Econ 2011; 14: 238-244.
• 74 McCullagh L. et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics 2009; 27: 829-846.
• 75 Ryttberg L. et al. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 601-615.
• 76 Wolowacz SE. et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009; 311: 194-212.
• 77 Wolowacz SE. et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients age d over 75 years or w ith moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost 2010; 103: 360-371.
• 78 McDonald H. et al. Cost-Effectiveness of Rivaroxaban in the Prevention of Venous Thromboembolism: A Canadian Analysis using the Ontario Ministry of Health Perspective. J Med Econ. 2012 Epub ahead of print.
• 79 Kohn LT. et al. Committee on Quality of Health Care in America, Institute of Medicine. To err is human: building a safer health sys- tem. Washington, DC: National Academy Press; 2000. Executive summary available at http://books.nap.edu/catalog/9728.html Accessed February 10th, 2012.
• 80 Institute of Medicine. Preventing medication errors: quality chasm series. Washington, DC: National Academy Press; 2006 Brief report available at http://www.iom.edu/Reports/2006/Preventing-Medication-Errors-Quality-Chasm-Series.aspx Accessed February 10th, 2012.
• 81 Bauer JB. et al. Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital. Am J Health Syst Pharm 2008; 65: 1643-1647.
• 82 Cronin M. et al. Implementation of a multidisciplinary, pharmacy-led, thromboprophylaxis program in total-joint arthroplasty patients. Am J Health Syst Pharm 2009; 66: 171-175.
• 83 Dobesh PP, Stacy ZA. Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. J Manag Care Pharm 2005; 11: 755-762.
• 84 Galanter WL. et al. Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. Am J Health Syst Pharm 2010; 67: 1265-1273.
• 85 Sobieraj DM. Development and implementation of a program to assess medical patients' need for venous thromboembolism prophylaxis. Am J Health Syst Pharm 2008; 65: 1755-1760.
• 86 Chisholm-Burns MA. et al. Economic effects of pharmacists on health outcomes in the United States: A systematic review. Am J Health Syst Pharm 2010; 67: 1624-1634.
• 87 Chisholm-Burns MA. et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med Care 2010; 48: 923-933.
• 88 Kaboli PJ. et al. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med 2006; 166: 955-964.
• 89 Giberson S. et al. Improving Patient and Health System Outcomes through Advanced Pharmacy Practice. A Report to the U.S. Surgeon General. Office of the Chief Pharmacist. U.S. Public Health Service. Dec 2011.
• 90 Support Letter from the US Surgeon General for Pharmacist Provider Status. Available at http://www.usphs.gov/corpslinks/pharmacy/comms/sgreport2011.asp Accessed February 10th, 2012.
• 91 National Safety Council data. Available at http://www.nsc.org/news_resources/injury_and_death_statistics/Pages/EstimatingtheCostsofUnintentionalInjuries.aspx Accessed February 10th, 2012.
• 92 Amorosi SL. et al. Cost analysis of „bridging therapy” with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. Am J Cardiol 2004; 93: 509-511.
• 93 Fanikos J. et al. Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol 2004; 93: 247-250.
• 94 Spyropoulos AC. et al. A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation. Pharmacotherapy 2004; 24: 649-658.
• 95 Spyropoulos AC. et al. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004; 125: 1642-1650.
• 96 Geerts WH. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (03) 338S-400S.
• 97 Prandoni P. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199-205.
• 98 Goldhaber SZ. et al. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.
• 99 Kniffin Jr WD. et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994; 154: 861-866.
• 100 Berghaus TM. et al. Echocardiographic evaluation for pulmonary hypertension after recurrent pulmonary embolism. Thromb Res 2011; 128: e144-147.
• 101 Surie S. et al. Active search for chronic thromboembolic pulmonary hypertension does not appear indicated after acute pulmonary embolism. Thromb Res 2010; 125: e202-205.
• 102 Ewen EF. et al. Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention. J Interv Cardiol 2009; 22: 266-273.
• 103 Linkins LA. et al. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
• 104 Kiser TH. et al. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2008; 28: 1115-1124.
• 105 Warkentin TE. et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (06) 340S-80S.
• 106 Hirsh J. et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (06) 141S-59S.
• 107 Lubenow N. et al. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 03: 2428-2436.
• 108 Jaff MR. et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123: 1788-1830.